Chronister Connie L
The Eye Institute of the Pennsylvania College of Optometry, Philadelphia, Pennsylvania, USA.
Optometry. 2006 Sep;77(9):438-45. doi: 10.1016/j.optm.2006.06.005.
Cryptococcus neoformans is an opportunistic pathogen that can manifest in immunocompromised patients with acquired immune deficiency syndrome. Prevention of cryptococcosis and other opportunistic diseases is an objective in the management of human immunodeficiency virus (HIV)-infected patients. The goal of highly active antiretroviral therapy (HAART) is to reduce the viral loads and enhance CD4 counts in HIV-infected patients. These 2 mechanisms keep HIV-infected patients healthier and enhance their immune systems, thus reducing and often preventing opportunistic infections such as ocular cryptococcal infections. Discontinuation of HAART can lead to ocular opportunistic infections such as cryptococcal choroiditis.
Presented here is a case of a patient who was treated successfully with HAART of stavudine (D4T), abacavir (Ziagen), ritonavir (Norvir), and saquinavir (Invirase). His last CD4 count before HAART was discontinued was 131 cells/mm(3), and viral load was less than 50 copies/mL. He discontinued his HAART regimen for 2 years and presented to the emergency room with complaints of a severe headache with neck pain, lightheadedness, nausea, disorientation, and unsteady gait. Lumbar puncture results showed cryptococcal infection, and the patient was admitted for the treatment of cryptococcal meningitis with amphotericin B and 5-flucytosine. Cryptococcal choroiditis was diagnosed after treatment of the meningitis. After resolution, his resultant visual acuities were 10/350 in the right eye and 10/600 in the left eye. He is on a maintenance dose of antifungal therapy and has been reinitiated on HAART of abacavir/zidovudine/lamivudine (Trizivir) and lopinavir/ritonavir (Kaletra).
This case exemplifies the importance of HAART in the prevention of opportunistic infections, cryptococcal meningitis/choroiditis in particular. Eye care professionals can play a role in encouraging patients to comply with their HAART regimens.
新型隐球菌是一种机会致病菌,可在获得性免疫缺陷综合征的免疫功能低下患者中出现。预防隐球菌病和其他机会性疾病是人类免疫缺陷病毒(HIV)感染患者管理的一个目标。高效抗逆转录病毒疗法(HAART)的目标是降低HIV感染患者的病毒载量并提高CD4细胞计数。这两种机制使HIV感染患者更健康并增强其免疫系统,从而减少并常常预防机会性感染,如眼部隐球菌感染。停用HAART可导致眼部机会性感染,如隐球菌性脉络膜炎。
本文介绍了一例患者,该患者接受司他夫定(D4T)、阿巴卡韦(Ziagen)、利托那韦(Norvir)和沙奎那韦(Invirase)的HAART治疗成功。在停用HAART之前,他最后的CD4细胞计数为131个细胞/mm³,病毒载量低于50拷贝/mL。他停用HAART方案2年,因严重头痛伴颈部疼痛、头晕、恶心、定向障碍和步态不稳到急诊室就诊。腰椎穿刺结果显示隐球菌感染,该患者因隐球菌性脑膜炎接受两性霉素B和5-氟胞嘧啶治疗入院。在脑膜炎治疗后诊断为隐球菌性脉络膜炎。恢复后,他右眼的最终视力为10/350,左眼为10/600。他正在接受抗真菌维持治疗,并已重新开始使用阿巴卡韦/齐多夫定/拉米夫定(Trizivir)和洛匹那韦/利托那韦(Kaletra)的HAART治疗。
本病例例证了HAART在预防机会性感染,特别是隐球菌性脑膜炎/脉络膜炎方面的重要性。眼科护理专业人员可在鼓励患者遵守HAART方案方面发挥作用。